Oxford Centre for Diabetes, Endocrinology and Metabolism
OCDEM is a pioneering centre that combines clinical care, research and education in diabetes, endocrine and metabolic diseases. By promoting world-class research, we aim to enhance understanding of these diseases and to accelerate the search for new treatments and cures.
Head of OCDEM
-
David Ray
Professor of Endocrinology, Head of OCDEM, and Co-Director Sir Jules Thorn Sleep and Circadian Neuroscience Institute
Latest publications
-
Endocrine effects of heat exposure and relevance to climate change.
Journal article
Hannan FM. et al, (2024), Nat Rev Endocrinol, 20, 673 - 684
-
Lessons to learn from the 2024 NICE guideline on adrenal insufficiency.
Journal article
Dong J. and Tomlinson JW., (2024), Lancet Diabetes Endocrinol
-
The Diabetes Technology Society Error Grid and Trend Accuracy Matrix for Glucose Monitors.
Journal article
Klonoff DC. et al, (2024), J Diabetes Sci Technol
-
Going beyond randomised controlled trials to assess treatment effect heterogeneity across target populations.
Journal article
Lugo-Palacios DG. et al, (2024), Health Econ
Latest News
Under-40s diagnosed with type 2 diabetes have a mortality rate four times higher than the general population
24 October 2024
People diagnosed with type 2 diabetes before 40 years of age, have nearly four times the risk of death compared with the general UK population, a new study carried out at the University of Oxford’s Radcliffe Department of Medicine has found.
New Type 1 Diabetes Grand Challenge funding to develop drugs from bugs
22 October 2024
Today the Type 1 Diabetes Grand Challenge, a trailblazing partnership between the Steve Morgan Foundation, Diabetes UK, and Breakthrough T1D (formerly JDRF) has announced funding for a cutting-edge research project led by researchers in the Radcliffe Department of Medicine, which could bring us closer to a cure for type 1 diabetes.
Patients receiving steroids are more than twice as likely to develop diabetes, UK study has found
10 September 2024
Patients who are being treated with systemic glucocorticoids are more than twice as likely to develop diabetes as those not receiving the treatment, a new study by researchers at the Radcliffe Department of Medicine’s Diabetes Trial Unit has found.
Jeremy Tomlinson awarded Outstanding Chief Investigator in NIHR celebration
23 July 2024
Congratulations to Professor Jeremy Tomlinson on winning an award for ‘Outstanding Chief Investigator’ from the National Institute of Health and Care Research’s (NIHR) Thames Valley and South Midlands Clinical Research Network (LCRN).
OCDEM Vacancies
Events
View previous and upcoming events in OCDEM.